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Adenovirus infectionConditionally-replicating adenoviruses (CRAds) and other oncolytic viruses replicate selectively in tumor cells,
presenting a potential cancer treatment approach. To optimize application of these viruses, understanding
of early spread of these viruses in target cells is important. Here we used a recombinant adenovirus expressing
enhanced jellyﬁsh green ﬂuorescent protein (EGFP) in place of the EIA and EIB genes (AdEGFPuci). Infection
of susceptible cells (AD-293) under plaque formation conditions (MOIbb1) on gridded culture dishes and
daily monitoring allowed visualization of initially infected cells, as well as spread to neighboring cells. We
determined key parameters of early infection, including the rate and efﬁciency of spread from the initially
infected cell to other cells. It was noteworthy that a minority of initially infected cells ultimately resulted in
plaques. The approaches elucidated here will be useful for determining early infection parameters for CRAds
of therapeutic interest.
© 2011 Elsevier Inc. All rights reserved.Introduction
Oncolytic viruses that replicate selectively in and lyse tumor cells
have been of considerable interest as novel approaches to cancer
therapy (Chiocca, 2002; Wong et al., 2010). Their side effects may
be less severe than traditional cancer treatments such as chemother-
apy, surgery, and radiation. Extensive laboratory research and clinical
trials have been conducted with several engineered oncolytic viruses
based on adenovirus, reovirus, herpes simplex virus type I, poxvirus,
poliovirus, Newcastle disease virus, measles virus, and vesicular
stomatitis virus (Alemany, 2007; Garber, 2006; Kirn et al., 1998; Lin
and Nemunaitis, 2004; Parato et al., 2005; Russell and Peng, 2007;
Toth et al., 2011).
Conditionally-replicating adenoviruses (CRAds) have been exten-
sively studied as oncolytic viruses (Toth et al., 2010). CRAds typically
lack the EIB and/or EIA genes; these viral genes inactivate the cellular
p53 and RB tumor suppressor genes that are frequently mutated or
inactivated in human cancers. Thus CRAds will replicate in tumor
cells lacking p53 and/or Rb, although other mechanisms of tumor
selectivity may be operative (Hall et al., 1998; Lane, 1998; Turnell
et al., 1999). In particular Adenovirus dl1520 (ONYX-015), defective
in the EIB 55 Kd protein, has been studied in vitro and in vivo
(Bischoff et al., 1996; Kirn et al., 1998). While Addl1520 and similarrights reserved.viruses have shown some efﬁcacy in Phase I clinical trials on cancer
patients, so far larger trials have not demonstrated sustained and
reliable treatment success (Liu and Kirn, 2008; Ries and Brandts,
2004). One contributory factor could be that the kinetics of oncolytic
virus spread in tumors is not well understood, so optimal methods
of delivery may not have been employed.
One approach to understanding kinetics of viral spread has been
through mathematical modeling. Previously mathematical analyses
of experimentally measured spreading for several viruses, including
human cytomegalovirus (Lam et al., 2006), vesicular stomatitis virus
(Haseltine et al., 2008) and T7 bacteriophage (Fort, 2002; Fort and
Mendez, 2002; Yin and McCaskill, 1992; You and Yin, 1999), have
generatedmodels for spread and plaque formation.We havemodeled
oncolytic virus spread in tumor cells and obtained interesting predic-
tions (Komarova and Wodarz, 2010; Wodarz, 2003; Wodarz and
Komarova, 2009; Zurakowski and Wodarz, 2007). However applica-
tion of the modeling to particular oncolytic viruses requires empirical
determination of key parameters in the models.
Another approach recently employed by several research groups
(including the experiments described here) involves generation of
recombinant CRAds expressing ﬂuorescent proteins (Borovjagin
et al., 2010; Hofacre and Fan, Unpublished results; Le et al., 2006a;
Ono et al., 2005; Ugai et al., 2010). Infected cells can be detected by
ﬂuorescence under UV illumination, and importantly cells or cultures
can be sequentially imaged at different times, allowing temporal
tracking of viral infection (Le et al., 2006b; Ono et al., 2005). We
have used this approach to characterize very early events in CRAd
virus infection and spread.
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expressing enhanced jellyﬁsh green ﬂuorescent protein (EGFP) in
the context of an adenovirus type 5 vector defective in EIA and
EIB (AdEGFPuci). Infection of AdEGFPuci onto complementing cells
(AD-293) at low multiplicity in gridded dishes under conditions of
plaque formation (MOIbb1) followed by sequential daily monitoring
for infected cells allowed determination of several key parameters
and properties of AdEGFPuci in these cells. The approaches elucidated
here will be useful for determining early infection parameters for
CRAds such as Addl1520.
Results
Determination of early kinetic parameters of adenovirus infection in
AD-293 cells
In these experiments we established a system to study the kinetics
of establishment and spread of CRAd infection. Such information
would be important for understanding spread of oncolytic adenovi-
ruses such as dl1520 in vivo. We employed a recombinant adenovirus
type-5 expressing EGFP gene in place of EIA and EIB (AdEGFPuci,
Fig. 1). While removal of the viral sequences was necessary to accom-
modate the EGFP gene within the packaging limits for adenovirus,
AdEGFPuci will replicate in human 293 embryonic kidney cells
that constitutively express adenovirus EIA and EIB viral proteins
(Graham et al., 1977). AdEGFPuci replicated efﬁciently in 293 cells,
giving viral stocks with titers of 109–1011 pfu/ml.
In this study establishment and spread of AdEGFPuci was carried
out under conditions of very low multiplicity infection of HEK293
cells in monolayer, under plaque formation conditions (including
overlay with 0.65% agar) (Graham and van der Eb, 1973). The 293
cells were AD-293 cells obtained from a commercial supplier (Agilent
Technologies, La Jolla, CA). A titered AdEGFPuci stock was diluted and
infected onto AD-293 cells in 60 mm tissue culture dishes with 2 mm
grids under standard conditions. The AdEGFPuci dilutions were cho-
sen so that less than 30% of the grid squares ever showed an infected
cell; under these conditions it was very likely that any infected cells
appearing in a square at any time resulted from one initial infection.
The disheswere scanned under UV illumination daily, and each square
was scored for the presence or absence of green (virus-infected) cells.
Results from two infections are shown in Fig. 2A. Grid squares with
one or a small number of cells are shown as green dots, while those
with larger numbers of green cells (developing plaques) are indicated
by stars. In one experiment (Experiment 4) the numbers of ﬂuores-
cent cells in each square were scored until they exceeded 10 cells.
The cumulative number of grid squares showing evidence for infec-
tion with respect to days post-infection is shown in Fig. 2B. In theseCMV 
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Fig. 1. Organization of AdEGFPuci. Schematic diagram of the EGFP recombinant Ad
viruses, AdEGFPuci (ΔE1A/E1B), is shown. For reference the transcriptional map of
adenovirus is shown at the top of the ﬁgure. The adenovirus genome contains early
(E1–4), intermediate (IX and IVa2) and late (L1-5) genes ﬂanked by left and right
inverted terminal repeats (LITR and RITR, respectively). MLP: major late promoter,
Ψ packaging signal.low multiplicity infections, the time between initial infection and ap-
pearance of green ﬂuorescence was 2 days±1 day (Fig. 2B). This lag
likely was inﬂuenced by the average time for entry and uncoating of
virus into the cells, as well as the time required for expression of
the viral genome and build-up of EGFP to levels where ﬂuorescence
could be detected. (Since EGFPwas driven by the CMV promoter, tran-
scription of EGFPmRNA should have occurred with “immediate early”
kinetics.) Surprisingly under these conditions aminority (28.1±4.0%)
of initial infections progressed to spreading infection and a viral
plaque (Fig. 2B).
Several patterns of infection within individual grid squares were
observed over time, as shown in Figs. 3A and B. In virtually all cases,
infection within a square began with one ﬂuorescent cell, as would
be expected for the low multiplicity of infection used. In some cases
the individual infected cell persisted for a few days (or longer)
and then it disappeared — mostly like due to lysis of the infected
cell (pattern A). This could represent infection of a cell with a defec-
tive AdEGFPuci genome, or productive infection that did not success-
fully spread. A second pattern (B) started with one infected cell,
followed by subsequent appearance of additional ﬂuorescent cells,
and ultimately a large region of local infection — i.e. a viral plaque.
At the viral plaque stage, cytopathic effect (CPE) in the region of
infection was visible by light microscopy, and ultimately a cleared
region was evident — surrounded by green ﬂuorescent cells. In
another pattern (C) a grid square showed an infected cell that
persisted for a few days, after which it disappeared (presumably
due to lysis); however subsequently another infected cell appeared
which either disappeared after a few days (pattern C), or it progressed
to a spreading infection and formation of a plaque (pattern D). We
interpret patterns C and D as showing an initially infected cell that
spread infection to another cell, which either did (pattern D) or did
not (pattern C) result in widespread infection and development of a
plaque. The data for all of the infections are presented in Supplemental
Data — Table S1, and the relative frequencies of the different patterns
will be presented below.
Analysis of the kinetics of infection in the infected grid squares
with particular patterns allowed determination of additional parame-
ters of initial infection. The distribution of the number of days that the
initially infected cell persisted in grids with patterns C and D is shown
Fig. 4A. In these squares the initially infected cell was clearly produc-
tively infected since it spread infection to an additional cell(s). At the
same time the fact that the initially infected cell disappeared before
appearance of secondarily infected cells allowed estimation of the
lifetime of the initially infected cells. The results indicated that an ini-
tially infected ﬂuorescent cell persisted for 2.5±1 days on average
before it dies. Since the average time between infection and appear-
ance of detectable ﬂuorescence was 2±1 days (Fig. 2B), the average
life of an initially infected AdEGFPuci infected cell was 4.5±2 days
under these conditions, assuming that binding, penetration and
uncoating were relatively rapid— 2 days before it showed green ﬂuo-
rescence, and 2.5 days after it turned green.
For infected grid squares with patterns C and D, the number of
days that a grid showed no ﬂuorescence after disappearance of
the initially infected cell before appearance of a secondarily infected
cell(s) is plotted in Fig. 4B. This was typically 1 day (76.9±0.9%).
Thus, on average the secondarily infected cells in pattern C and D
grids appeared at 5.5 days post-infection. Since it took infected cells
2 days to show EGFP ﬂuorescence (Fig. 2B), the initially infected
cells released infectious virus that spread to another cell at approxi-
mately 3.5 days in order for secondarily infected cells to appear at
5.5 days.
There were rare cases where multiple infected cells appeared in a
grid without a single infected cell appearing ﬁrst (pattern E, not
shown, 2 cases out 265, b1%). In both of these cases the multiply
infected cells ﬁrst became evident at 7 and 9 days post-infection
respectively. We attribute them to instances where the initially
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Fig. 2. Kinetics of AdEGFPuci infection under conditions of plaque formation. (A) Representative infection of AD-293 cells seeded onto gridded tissue culture dishes was infected by
a diluted stock of AdEGFPuci under plaque formation conditions (MOIbb 0.01) and the dish was observed under UV illumination for infected cells every 24 h. Results for each grid
square for the ﬁrst 8 days are shown. The dots indicate the presence of a ﬂuorescent cell. The stars represent the presence of multiple ﬂuorescent cells and spreading infection — i.e.
a plaque. (B) Data from one of three similar experiments (Experiment 1) were collected in the panel on the left, and the cumulative number of squares (out of 540) showing one or
more infected cells is shown (diamonds). The cumulative number of grid squares showing plaques is also shown (squares). For these experiments when the number of infected
cells in a grid was >2, the grid was scored as one with spreading infection but the number of infected cells was not recorded. For the ﬁrst three experiments, the percentage of
grids showing initial infection that progressed to plaques was 27.8±4.8%. Data from a fourth experiment is shown on the right – in this experiment the number of infected
cells were also counted and recorded for those grids with spreading infection (>2 infected cells) for the ﬁrst 16 days (see Fig. 6).
91A. Hofacre et al. / Virology 423 (2012) 89–96infected cell was not observed, either due to observational error,
or because it died soon after it began to show green ﬂuorescence
and between observations.
Patterns of spread from initially infected cells
The patterns of spread from initially infected cells for AdEGFPuci
in AD-293 cells, using results from four independent experiments
are shown in Fig. 5A. The fates of the initially infected cells were
categorized as spread of infection to 0, 1, 2 or >2 secondarily infected
cells (1→0, 1→1, 1→2 and 1→>2, respectively) and the number
of events in each category is shown. Secondary infections were
characterized as the state of infection (number of ﬂuorescent cells)
3–5 days after appearance of an initially infected cell. One area of
uncertainty was for cells in pattern A, if the initially infected cell
persisted for more than 3 days. These grid squares could represent
cells infected with a defective virus (green ﬂuorescence but nolysis), or they could reﬂect spread of infection from the originally
infected cell to a single secondarily infected cell where the originally
infected cell lysed on the same day that the secondarily infected
cell began to show ﬂuorescence. As a simplifying assumption, grid
squares in pattern A where the single infected cell persisted
for more than 3 days were categorized as spread of infection to one
additional cell. Thus grid pattern A was subdivided into pattern A1
(single ﬂuorescent cell persisting for ≤3 days) and pattern A2 (single
ﬂuorescent cell persisting for≥4 days); pattern A1 was assigned to
the 1→0 category, and A2 was assigned to the 1→1 category.
Fig. 5A also shows the ultimate results of the infections for each
grid at 14 days post-infection, where spreading infection (S) resulted
in a plaque while abortive infection (A) resulted in no plaque. As
mentioned above, the overall percentage of initially infected cells
that gave rise to spreading infection and a plaque was 28.1±4%. For
grids where the initially infected cell spread infection to >2 cells,
spreading infection and a plaque resulted 100% of the time (37
1 2 3 4 5 6 7 8 (days)
= single cell = plaque
A1 A2
1 2 3 4 5 6 7
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A B
Fig. 3. Patterns of AdEGFPuci infection. (A) Diagrams of patterns of infection for AD-293 infected with AdEGFPuci (Fig. 2) are shown. In virtually all cases, grid squares initially
showed a single infected cell. Pattern A, persistence of one infected cell for several days, represented by a triangle, followed by disappearance of the ﬂuorescent cell. Pattern B,
one infected cell followed by additional ﬂuorescent cells, which ultimately led to a viral plaque, represented by a star. Pattern C, one infected cell that persisted for several days,
then disappeared for at least one day, before ﬂuorescence reappeared on a subsequent day in the same square, but then ultimately ﬂuorescence ceased. Pattern D, similar to pattern
C, except that additional ﬂuorescent cells reappeared in the square, ultimately resulting in a plaque. Pattern A and B may also be represented by two subcategories, A1 and A2, that
could result from overlap of EGFP ﬂuorescence from the primary infected cell simultaneously with a neighboring secondarily infected cell rather than a singly infected cell that
persisted for an extensive number of days. (B) Photo montages (100×) of grids showing the patterns diagramed in (A).
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there was an intermediate probability of spreading infection (53%,
17/32 grids). It was noteworthy that a signiﬁcant fraction of these
grids did not progress to spreading infection (15/32 grids). If the ini-
tially infected cell spread infection to just one secondary cell, then the
overall rate of the secondarily infected cell giving rise to spreading
infection and a plaque was 24.7% (24/97 grids) — slightly lower but
not statistically different from the overall rate for the single infected
cells in the initial infection.
In the analysis in Fig. 5A, we were concerned that the simplifying
assumption (assigning grids with pattern A2 to the 1→1 category)
could have included abortively infected cells that never spread infec-
tion to another cell. This could have at least partially caused the
apparently lower efﬁciency of spreading infection in the 1→1 catego-
ry compared to the initially infected cells. To circumvent this concern,
we analyzed data from the subset of grid patterns C and D, where
a single secondarily infected cell appeared after disappearance of
the initially infected cell (Fig. 3). For these squares there was no un-
certainty about the replication competency of the virus in the initially
infected cell. Patterns of spread of infection for the next (tertiary)
round of infection from these cells are shown in Fig. 5B. The analysis
from Fig. 5B indicated that the secondarily infected single cells
behaved essentially the same as the initially infected cells in terms
of the efﬁciency with which they spread infection to tertiarily
infected cells, and the likelihood of giving a spreading infection. (In
fact most of the events in the 1→1 category of Fig. 5A came from
grid patterns C and D (97) and fewer came from pattern A2 (8)).
Spread of infection — comparison with a stochastic null model
The data gathered from four independent experiments (Fig. 2A
and Table S1) showed various pathways that AdEGFPuci infection in
AD-293 cells can follow, and provided a statistical description of the
different outcomes. In particular, we found that infection always
started with one infected cell, and in 28±4% of the cases spreading
infection occurred and a plaque was formed within 14 days of
observation. A similar percentage (21±10%) of initially infected
cells resulted in plaques in a fourth experiment, where the numbers
of infected cells were recorded for grid squares with >2 secondarilyinfected cells. When initial infection spread to 2 infected cells, in
more than a half of the cases spreading infection and a plaque
resulted. It was also noteworthy that an initially infected cell imme-
diately spread infection to >2 cells in a minority (13.4%) of times.
A striking observation was that when infection spread to three
or more infected cells, this resulted without exception in plaque
formation.
Here we show that these observations are incompatible with a
simple null-model whereby infection from the initially infected cell
spreads stochastically according to a so-called “birth-death” process.
In the null-model, the probability of infection extinction can be pre-
dicted starting from the number of cells secondarily infected from
an initially infected cell. As described above the probability of an ini-
tially infected cell forming a plaque was found to be 28%, which cor-
responded to an extinction probability p1 of ~0.72. As shown in
Fig. 5B, when initial infection spread to one secondarily infected
cell, the extinction rate was similar to p1. If the same laws of spread
apply to grid squares where initial infection spread to other numbers
of cells, the probability of infection extinction starting with i second-
arily infected cells would be pi≥p1i . In particular in a non-spatial
model, where infected cells spread infection according to laws of
mass-action, we have pi=p1i , and in spatial models the probability
of extinction would be higher. As a consequence, the probability
of plaque formation when there are i secondarily infected cells
would be lower than 1–(0.72)i (Fig. 6A). The number distribution of
secondarily infected cells taken from Experiment No. 4 is shown
in Fig. 6B, where 16 grid squares showed spread of infection
to >2 cells. Calculation of the probabilities for each value of i
(3 through 10) and weighting for the number of grids in each i
category resulted in an overall predicted extinction probability for
squares with >2 secondarily infected cells to be 0.19 (3 out of 16
squares), compared to the observed 0%. If the number distribution
of secondarily infected cells in experiments 1–3 was similar to
experiment 4, then the null-model would predict 7 out of 37 grid
squares with >2 secondarily infected showing extinguishments
of infection, while none were observed. Thus the results did not
ﬁt the stochastic null-model when the number of secondarily
infected cells was >2, although they were consistent with it for 1
or 2 secondarily infected cells.
A
Lifespan of Initial Fluorescent Cells
0
5
10
15
20
25
30
35
40
45
50
1 2 3 4 5 6 7 8
Days
N
o.
 o
f G
rid
 S
qu
ar
es
B
Time Between Fluorescence(1o – 2o Infected cells)
0.0
20.0
40.0
60.0
80.0
100.0
1 2 3 4 5 6 7 8
Pe
rc
en
t o
f G
rid
 S
qu
ar
es
Days
Fig. 4. Lifespan of initially infected cells. (A) Data from Experiments 1–4 (Fig. 2) were
analyzed for the length of persistence of initially infected cells. The number of days
that the initially infected cells persisted in grid squares with patterns C and D of
Fig. 3 are shown. (B) For grid squares with patterns C and D, the number of days
between disappearance of the initially infected ﬂuorescent cell and reappearance of
one or more secondarily infected cells is shown. Results are plotted as percent of the
total grid squares analyzed (129).
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In these experiments, we characterized the initial dynamics of
infection for the CRAd AdEGFPuci under conditions of plaque
formation — i.e. low MOI under an agar overlay. The cells used were
AD-293, a derivative of HEK293 (293) cells that constitutively express
Ad EIA and EIB proteins (Graham et al., 1977). These cells could
support replication of AdEGFPuci, which contained EGFP inserted in
place of the EIA and EIB coding regions. Performing the infections
on gridded culture dishes allowed repeated monitoring at daily
intervals for signs of infection (green ﬂuorescence). This approach
allowed determination of several parameters and properties of initial
AdEGFPuci infection, including patterns of infection spread, and some
of the results were surprising. First, a minority (~28%) of initially
infected cells resulted in spreading infection and a plaque. Second,
spread of infection from initially infected cells to secondarily infected
cells was generally inefﬁcient — in ~74% of cases the initially infected
cell spread infection to no or only one secondary cell. Third, the
probability of infection leading to spreading infection and a plaque
did not ﬁt a stochastic null-model when initial infection spread
to more than two secondarily infected cells — in 100% of these cases
plaques resulted. In this system, the average time for appearance
of green ﬂuorescence was 2±1 days, and the average lifetimes ofinitially infected cells were 4.5±2 days. The average time for spread
of infection to secondarily infected cells was~3.5 days.
The low efﬁciency of spread of infection from an initially
infected cell to secondary cells observed here was surprising. The
traditional view is that an infected cell produces many infectious
progeny viruses (i.e. a large burst size), so that multiple secondarily
infected cells are expected. However for eukaryotic viruses such
as adenovirus, this has not been carefully evaluated for conditions
of plaque formation per se (Mittereder et al., 1996). The use of
EGFP-expressing virus allowed systematic identiﬁcation of all ini-
tially infected cells and tracking of their fates, and this approach
uncovered the discrepancy between number of initially infected
cells and ultimate plaque number. The use of AD-293 cells may
have facilitated this analysis. In these cells it was possible to distin-
guish primary from secondarily infected cells due to the relatively
long time between initial and secondary infection (3.5 days). In pre-
liminary experiments we have tested infection of AdEGFPuci in the
original 293 cells. In 293 cells the infection appeared to spread more
rapidly, and more secondarily infected cells resulted from each ini-
tially infected cell. The reason for the difference between AD-293
and 293 cells is under investigation. One possibility could be that
the levels of EIA and EIB proteins expressed in these cells differ
but RT-PCR did not detect differences in levels of EIA transcripts
(Hofacre and Fan, Unpublished results).
One potential factor in these experiments could have been that
repeated scanning of the infected cultures under UV light might
have mutagenized the virus or infected cell, resulting in the discrep-
ancy between number of initially infected cells and resulting
plaques. However, the scanning was conducted rapidly at low mag-
niﬁcation, which minimized the UV exposure to any given cell or
virus. To directly address this possibility, duplicate infections of
AdEGFPuci on AD-293 cells under plaque formation conditions
were established; one set of cultures was monitored daily under
UV for green ﬂuorescence while the others were not. At 11 days
post-infection both sets were assayed for plaques by GFP ﬂuores-
cence. The titer of the AdEGFPuci stock measured on cells without
UV monitoring was 5.3×108 pfu/ml, while the same stock measured
on the cells with daily UV monitoring gave a similar titer of
4.9×108 pfu/ml, within the margin of experimental error. Therefore
daily UV monitoring did not appreciably affect the efﬁciency of
plaque formation.
It was necessary to study infection of AdEGFPuci in EIA and EIB
complementing cells such AD-293 because AdEGFPuci does not
encode EIA and EIB proteins. The fact that AD-293 or 293 cells consti-
tutively express EIA and EIB proteins could inﬂuence the rates of
replication and spread compared to wild-type adenovirus infected
into cells that do not express these proteins. In wild-type adenovirus
infection EIA is the ﬁrst viral transcript expressed, and the EIA
proteins are required for transcriptional induction of other viral
early proteins including those encoded by EIB. Thus AdEGFPuci
might replicate more rapidly in AD-293 or 293 cells than wild-type
virus infected into cells that do not constitutively express EIA and
EIB. We have generated a recombinant adenovirus expressing EGFP
as well as EIA and EIB (AdEGFPwt, (Hofacre and Fan, Unpublished
results)). This virus replicates efﬁciently in AD-293 cells, and it also
forms plaques in some but not all non-complementing cells (e.g.
HeLa and MCF7, but not A549). Infection of MCF7 cells with
AdEGFPwt also showed a discrepancy between number of initially
infected cells and resulting plaques (ca. 26%), indicating that the re-
sults reported here reﬂect a more general phenomenon. In future
experiments it will be possible to use the approaches described
here to determine the parameters of early infection for a virus that
resembles wild-type adenovirus in terms of EIA and EIB expression.
The motivation for these studies was to understand the pa-
rameters of viral infection and spread for oncolytic adenoviruses
such as dl1520. To this end we have also generated a recombinant
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values in the box represent the number of infected cells, values below each box represent the number of infectious events observed in the boxed category, after each round of
infection by AdEGFPuci in AD-293 cells. Percentages of the infected cells showing each fate are indicated over the arrows to each secondary infection category; the errors
among the different experiments are indicated (standard error of the mean). (B) The spread of infection from a secondarily infected cell when there is only one cell secondarily
infected cell. The ﬂow chart is equivalent to that represented above in (A), except the fates of the secondarily infected single cells are expanded upon. The percentages of each
fate for secondary singly infected cells were not statistically different from those for the primary singly infected cells in (A).
94 A. Hofacre et al. / Virology 423 (2012) 89–96adenovirus expressing EGFP in place of EIB, but wild-type for
EIA (Addl1520EGFPΔE3 (Hofacre and Fan, Unpublished results)).
This virus replicates in 293 and AD-293 cells, as evidenced
by CPE at high multiplicity infections and plaques at lower MOIs.
As described in Fig. 6, we also analyzed the stochastics of early
viral infection. The overall probability of extinction of infection
from an initially infected cell infected at low MOI (one infectious
virus per cell for any cell infected) was determined to be 0.72
±0.04 (Fig. 2). When the initially infected cell spread infection
to one or two cells, the fates of those infections were consistentwith a stochastic null-model, in which the secondarily infected cells
behaved like the initially infected cell (Fig. 5). However, when infec-
tion spread to >2 cells, the results were inconsistent with the
stochastic null-model; in all of these cases spreading infection and
a plaque resulted. A likely explanation was that when infection
spread to >2 cells, some of those cells were infected by more
than one virus (i.e. an MOI>1). The amount of infectious virus pro-
duced per infected cell typically increases as MOIs increase (e.g. 1
vs. 10) (Mittereder et al., 1996), which would reduce the extinction
probability p.
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Fig. 6. Probability of a spreading AdEGFPuci infection. (A) The probability of plaque for-
mation when an initially infected cell spreads infection to different numbers of second-
arily infected cells according to a stochastic null-model is shown (circles). The
observed values are shown (squares). (B) The distribution of AdEGFPuci virus spread
from primary infected cells to secondarily infected cells in grid squares where the num-
ber of secondarily infected cells was >2 (Experiment 4, 16 squares).
95A. Hofacre et al. / Virology 423 (2012) 89–96Recently other researchers have also employed CRAds expressing
expressing ﬂuorescent proteins (e.g. EGFP or RFP), either as fusions
to viral structural proteins (Le et al., 2006a, 2006b) or, as in this
study, as independent proteins driven by the CMV promoter (Ono
et al., 2005) to characterize virus infection. Efﬁciency of infection
and spread in A549 lung cancer cells (Ugai et al., 2010), glioblastoma
cell lines or primary tumor cells (Idema et al., 2010) , or in an ortho-
topic breast cancer tumor model (Borovjagin et al., 2010) were car-
ried out. In particular Idema et al. (Idema et al., 2010) measured
parameters for CRAd spread after initial infection, and they used the
measured values to test mathematical models for oncolytic virus
spread. The studies described here differ from the previous reports
in that infections were conducted at extremely low MOIs, which in-
sured that any infected cell was infected with only one infectious
virus, and that surrounding cells were not infected by input virus.
This allowed characterization of the spread of infection from an
infected cell to neighboring uninfected cells. In contrast the other
studies were either conducted at high MOIs (Ugai et al., 2010), or at
MOIs of 1 but where neighboring cells were also likely infected
(Idema et al., 2010).
In summary, these studies have allowed elucidation of several key
parameters and principles for establishment of spreading infections
in the AdEGFPuci — AD-293 system. While the values of these param-
eters are likely to differ for other virus — cell systems, the same
underlying principles are likely to apply. Analogous measurement of
these parameters will provide insight into the spread of wild-type
adenovirus, and also oncolytic adenoviruses such as dl1520 in more
relevant target cells.Materials and methods
Cell lines
AD-293 cells used in these studies and were purchased commer-
cially (Agilent Technologies — La Jolla, CA). AD-293s are derived
from the commonly used HEK293 cell line, but have improved cell
adherence and plaque formation properties. HEK293 cells are
human embryonic kidney cells transformed by sheared adenovirus
type 5 DNA (Graham et al., 1977). AD-293 cells, like HEK293 cells,
express the adenovirus E region (EIA and EIB), allowing the produc-
tion of infectious virus particles when they are infected or transfected
with E1-deleted adenovirus vectors. AD-293 cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS). AD-293 cells were cultured at 37 °C,
95% humidity, and 5% CO2.Adenovirus
A recombinant adenovirus type-5 (Ad5) virus that expresses
enhanced jellyﬁsh green ﬂuorescent protein (EGFP), in which
the EGFP gene driven by the immediate early promoter of human
cytomegalovirus (CMV) was substituted into the EIA and EIB
regions (AdEGFPuci), was used in these studies (a gift from
Drs. Toai Nguyen and Luis Villarreal, Center for Virology Research,
UCI). Though removal of the viral sequences was necessary to
produce a recombinant viral DNA within the packaging limits for
adenovirus, AdEGFPuci will replicate in HEK293 cells (Graham et al.,
1977). AdEGFPuci viral stocks, with titers of 109–1011 pfu/ml, were
generated from infected AD-293 cells and recovered from cultures
(when extensive CPE was evident) by freeze–thaw three times
followed by CsCl2 banding via previously established techniques
(Tollefson et al., 2007).Adenovirus infections and plaque assays
Adenovirus infections were performed as follows. 24 h prior
to infections, 5×105 AD-293 cells were seeded onto a 60 mm cell
culture dish with a marked grid of (2 mm squares)(Corning —
Corning, NY). 24 h post-seeding (cell density of ~70–80% conﬂu-
ence) 1 ml of dilutions of AdEGFPuci stocks (~102–101 pfu/ml dilu-
tions) were applied directly to the cell monolayers and incubated
while rocking at 37 °C, 95% humidity, and 5% CO2 for 1 h. Subse-
quently, non-absorbed virus was aspirated, and the cell monolayer
was overlaid with 3 ml of 0.65% agarose in 1× DMEM/10%
FBS. AdEGFPuci infected cells were cultured under the above condi-
tions (without rocking) for at 8 days or longer, and the cells were
fed by overlay with 2 ml–0.65% agarose/1× DMEM/10% FBS every
3–4 days.Quantiﬁcation of AdEGFPuci infection and plaque development
AdEGFPuci infected cells were scanned under UV illumination
daily (100× magniﬁcation) using an Axiovert 200M phase-
contrast ﬂuorescent microscope (Zeiss, Germany). Each grid square
was scored for the presence of green (virus-infected) cells and
monitored daily for at least 8 days or longer. Squares showing
AdEGFPuci infection (ﬂuorescent cells) were recorded at 24 h in-
tervals and compiled using Microsoft PowerPoint (see Fig. 2A).
The data sets were for four experiments and the subsequent
fates of each positive grid square are presented in Supplementary
Data — Table S1.
Supplementarymaterials related to this article can be found online
at doi: 10.1016/j.virol.2011.11.014.
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